Tag: development

CHIHUAHUA, México, July 25, 2025 (GLOBE NEWSWIRE) -- Grupo Bafar, S.A.B. de C.V. (BIVA: BAFARB), a leading and benchmark company in the national food sector, announced its results for the second quarter of 2025, highlighting sustained growth driven by innovation, digitalization, and expansion strategies across all its divisions.

該公司的主權財富策略早前亦獲媒體聚焦

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential ‘Disease X’. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO’s SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle delivery.